FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Delphi Management Partners VIII, L.L.C. 		2. Issuer Name and Ticker or Trading Symbol

TriVascular Technologies, Inc. [ TRIV ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

160 BOVET ROAD, SUITE 408,  		3. Date of Earliest Transaction (MM/DD/YYYY)

2/3/2016
(Street)

SAN MATEO, CA 94402
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   2/3/2016     U    3535910   D   (1) 0   I   See Footnotes   (2) (3)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
( 1)  These shares were disposed of pursuant to the merger agreement between the Issuer and Endologix, Inc. ("Endologix") (such transaction, the "Merger"). In connection with the closing of the Merger, the Reporting Persons received 0.631 share of Endologix common stock and $0.34 in cash for each share of Issuer common stock held by such Reporting Persons, for a total consideration of $4.95 per share based upon the closing price of Endologix common stock on February 2, 2016.
( 2)  These securities were directly held as follows: 1,464,553 shares by Delphi Ventures VII, L.P. ("Ventures VII"), 14,641 shares by Delphi BioInvestments VII, L.P. ("BioInvestments VII" and together with Ventures VII, the "Delphi VII Funds"), 2,036,831 shares by Delphi Ventures VIII, L.P. ("Ventures VIII") and 19,885 shares by Delphi BioInvestments VIII, L.P. ("BioInvestments VIII" and together with Ventures VIII, the "Delphi VIII Funds" and collectively with the Delphi VII Funds, the "Delphi Funds"). Delphi Management Partners VII, L.L.C. ("DMP VII") is the general partner of each of Ventures VII and BioInvestments VII and may be deemed to have sole voting and dispositive power over the securities held by the Delphi VII Funds. Delphi Management Partners VIII, L.L.C. ("DMP VIII") is the general partner of each of Ventures VIII and BioInvestments VIII and may be deemed to have sole voting and dispositive power over the securities held by the Delphi VIII Funds.
( 3)  Douglas A. Roeder, James J. Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D. are the managing members of each of DMP VII and DMP VIII and may be deemed to share voting and dispositive power over the securities held by the Delphi Funds. Such persons and entities disclaim beneficial ownership of the securities held by the Delphi Funds, except to the extent of any pecuniary interest therein.

Remarks:
In accordance with the terms of the merger agreement, Douglas A. Roeder resigned from his position as a member of the Issuer's Board of Directors, and any committees thereof, effective as of the closing of the Merger.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Delphi Management Partners VIII, L.L.C.
160 BOVET ROAD, SUITE 408
SAN MATEO, CA 94402
X

Delphi Management Partners VII, L.L.C.
160 BOVET ROAD, SUITE 408
SAN MATEO, CA 94402
X

DELPHI VENTURES VII L P
C/O DELPHI VENTURES
160 BOVET ROAD, SUITE 408
SAN MATEO, CA 94402
X

DELPHI VENTURES VIII LP
C/O DELPHI VENTURES
160 BOVET ROAD, SUITE 408
SAN MATEO, CA 94402
X

DELPHI BIOINVESTMENTS VII LP
C/O DELPHI VENTURES
160 BOVET ROAD, SUITE 408
SAN MATEO, CA 94402
X

Delphi BioInvestments VIII LP
C/O DELPHI VENTURES
160 BOVET ROAD, SUITE 408
SAN MATEO, CA 94402
X

ROEDER DOUGLAS A
C/O DELPHI VENTURES
160 BOVET ROAD, SUITE 408
SAN MATEO, CA 94402 		X X

BOCHNOWSKI JAMES J
C/O DELPHI VENTURES
160 BOVET ROAD, SUITE 408
SAN MATEO, CA 94402
X

DOUGLASS DAVID L
C/O DELPHI VENTURES
160 BOVET ROAD, SUITE 408
SAN MATEO, CA 94402
X

PAKIANATHAN DEEPIKA
C/O DELPHI VENTURES
160 BOVET ROAD, SUITE 408
SAN MATEO, CA 94402
X


Signatures
/s/ Matthew T. Potter, Attorney-In-Fact for Delphi Management Partners VIII, L.L.C. 2/4/2016
** Signature of Reporting Person Date

Matthew T. Potter, Attorney-In-Fact for Delphi Management Partners VII, L.L.C. 2/4/2016
** Signature of Reporting Person Date

Matthew T. Potter, Attorney-In-Fact for Delphi Ventures VII, L.P. 2/4/2016
** Signature of Reporting Person Date

Matthew T. Potter, Attorney-In-Fact for Delphi Ventures VIII, L.P. 2/4/2016
** Signature of Reporting Person Date

Matthew T. Potter, Attorney-In-Fact for Delphi BioInvestments VII, L.P. 2/4/2016
** Signature of Reporting Person Date

Matthew T. Potter, Attorney-In-Fact for Delphi BioInvestments VIII, L.P. 2/4/2016
** Signature of Reporting Person Date

Matthew T. Potter, Attorney-In-Fact for Douglas A. Roeder 2/4/2016
** Signature of Reporting Person Date

Matthew T. Potter, Attorney-In-Fact for James J. Bochnowski 2/4/2016
** Signature of Reporting Person Date

Matthew T. Potter, Attorney-In-Fact for David L. Douglass 2/4/2016
** Signature of Reporting Person Date

Matthew T. Potter, Attorney-In-Fact for Deepika R. Pakianathan 2/4/2016
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
TRIVASCULAR TECHNOLOGIES, INC. (NASDAQ:TRIV)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more TRIVASCULAR TECHNOLOGIES, INC. Charts.
TRIVASCULAR TECHNOLOGIES, INC. (NASDAQ:TRIV)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more TRIVASCULAR TECHNOLOGIES, INC. Charts.